The Food and Drug Department in the wake of information received from Health Canada on Health Hazard Evaluation conducted by both Health Canada and manufacturer Apotex is recalling APO Clindamycin Hydrochloride 150 and 300 mg; Batch Nos. HL 0314, HT 1470, HY 7888, and JC 7887.

According to a press release, the identified batches of Clindamycin active raw material and certain beta-antibiotics were found to have inadequate separation of these operations during manufacturing.  Consequently, cross-contamination is a risk although this was not categorically confirmed.  The release stated that “although the potential for serious adverse health consequences was unconfirmed and remote Apotex is voluntarily recalling the product as a precautionary measure, due to the sensitizing nature of the potential cross contamination.” Consequently, the department is calling on “all importers, pharmacies and health care providers to surrender the said batches of APO Clindamycin to the Food and Drug Department.

The department could be reached on telephone numbers 222-8857 and 222-8859.